Virological failure

AbelZeta Announces Two Abstracts Accepted for Presentation at the 65th ASH Annual Meeting

Retrieved on: 
Wednesday, November 22, 2023
Virological failure, San Diego Convention Center, Johnson & Johnson, B-cell lymphoma, ASH, Clinical research, Multiple myeloma, CD19, Research, Biology, Lymphoma, Exposition, Abstract, Clinical trial, CAR T cell, Society, Relapse, Patient, Pharmaceutical industry, Vaccine

and SHANGHAI, Nov. 22, 2023 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic products, announced today that two abstracts relating to its immuno-oncology drug development have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Diego, California, and online from December 9 to 12, 2023.

Key Points: 
  • and SHANGHAI, Nov. 22, 2023 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic products, announced today that two abstracts relating to its immuno-oncology drug development have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Diego, California, and online from December 9 to 12, 2023.
  • Session: 704.
  • The abstracts are available through the ASH online meeting program.
  • C-CAR039 and C-CAR066 have been out-licensed as part of a global collaboration and license agreement (excluding Greater China) with Janssen Biotech, Inc., a Johnson & Johnson company.

Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 8, 2023
Week, Patient, FDA, Research, Disposable household and per capita income, Standard of care, Immunodeficiency, SOC, Ageing, Bemnifosbuvir, Income tax, Food, RNA, Viral, Fast Track, Hepatitis C, Cirrhosis, BID, Doctor of Philosophy, Infection, Regulation of tobacco by the U.S. Food and Drug Administration, Development, Risk, Clinical trial, Atea, COVID-19, HCV, Security (finance), SVR, Second generation, Safety, Virological failure, Hospital, Administration, Death, Pharmaceutical industry, Cryptocurrency

BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or the “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.

Key Points: 
  • We’ve quickly completed enrollment of the   60-patient lead-in cohort and initial results are expected in early 2024," continued Dr. Sommadossi.
  • Currently, Atea anticipates providing an update after each of these interim analyses are completed with the first update expected to occur in the first quarter of 2024.
  • Cash, Cash Equivalents and Marketable Securities: $595.1 million at September 30, 2023 compared to $608.1 million at June 30, 2023.
  • Income Tax Expense: Income tax expense was $0.2 million for the quarter ended September 30, 2023 compared to a benefit of $3.8 million for the quarter ended September 30, 2022.

Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, August 8, 2023
Covid-19 hospital, Bemnifosbuvir, Patient, Risk, Arm, Income tax, Hospital, Week, New Drug Application, COVID-19, Atea, Viral, Fast Track, SOC, Virological failure, Infection, Disposable household and per capita income, Doctor of Philosophy, U.S. FDA, Congress, Development, ECCMID, Second generation, Standard of care, European, BID, Security (finance), Administration, SVR, Clutch (eggs), Adolescence, Research, FDA, Death, Regulation of tobacco by the U.S. Food and Drug Administration, Cirrhosis, HCV, Food, Safety, Pharmaceutical industry, Cryptocurrency

BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.

Key Points: 
  • BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.
  • During the second quarter of 2023, we began dosing HCV patients, and we look forward to reporting initial results from our lead-in cohort of approximately 60 patients by year-end 2023,” continued Dr. Sommadossi.
  • Interest Income and Other, Net: Interest income and other, net was $7.3 million for the quarter ended June 30, 2023 compared to $1.1 million for the quarter ended June 30, 2022.
  • Income Tax Expense: Income tax expense remained relatively consistent at $0.3 million for the quarter ended June 30, 2023 compared to $0.1 million for the quarter ended June 30, 2022.

Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination

Retrieved on: 
Thursday, June 15, 2023
Bemnifosbuvir, Hepatology, Week, Infection, Atea, Viral, Virological failure, Doctor of Philosophy, Hepatitis, Patient, SVR, Safety, HCV, World Health Organization, Pharmaceutical industry

BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the dosing of the first patient in the Phase 2 bemnifosbuvir and ruzasvir combination study for the treatment of Hepatitis C Virus (HCV) infection.

Key Points: 
  • “The initiation of this Phase 2 combination study marks an important clinical milestone for Atea,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals.
  • Patients will be administered 550 mg bemnifosbuvir in combination with 180 mg ruzasvir once-daily for eight weeks.
  • The primary endpoints of the study are safety and sustained virologic response (SVR) at Week 12 post-treatment.
  • Preliminary data from the 60 patient lead-in cohort are anticipated in the fourth quarter of 2023.

Atea Pharmaceuticals Highlights Strategic Priorities for 2023

Retrieved on: 
Monday, January 9, 2023
Fever Dream, Atea, HCV, Virological failure, Hospital, Merck, SVR, COVID-19, Viral load, Standard of care, Death, Safety, RZR, Risk, Hepatitis C, SOC, Rest, Patient, Week, Immunodeficiency, Second generation, Ritonavir, NS5A, HIV disease progression rates, DENV, Clinical trial, Doctor of Philosophy, BID, Pharmaceutical industry, Medical imaging, Vaccine

BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today provided an update on the company’s clinical development programs for 2023, including its strategic priorities and expectations for achievement of a variety of milestones.

Key Points: 
  • BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today provided an update on the company’s clinical development programs for 2023, including its strategic priorities and expectations for achievement of a variety of milestones.
  • An interim analysis is expected to be conducted in the second half of 2023.
  • Atea expects to initiate patient dosing of the Phase 2 study during the second quarter of 2023 with initial data anticipated in the fourth quarter of 2023.
  • Studies conducted by Atea have shown in vitro synergy from the combination of bemnifosbuvir and RZR in inhibiting HCV replication.

FDA Approves First Treatment for Common Type of Post-Transplant Infection that is Resistant to Other Drugs

Retrieved on: 
Tuesday, November 23, 2021
Patient, Research, Office of Inspector General, U.S. Department of Health and Human Services, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Review, Safety, Nausea, Virological failure, Death, Population, Center for Drug Evaluation and Research, Plasma, Taste, Diagnosis, China Biologic Products, Priority review, Cidofovir, Smokeless tobacco, Vaccine, Food, Infection, Center, DNA, Risk, Ganciclovir, Diarrhea, Valganciclovir, Cytomegalovirus, Dietary supplement, Vomiting, Foscarnet, FDA, Public health, Multimedia, Human services, Animal, CMV, Cosmetics, Breakthrough therapy, Fatigue, Pharmaceutical industry

"Cytomegalovirus infections that are resistant or do not respond to available drugs are of even greater concern.

Key Points: 
  • "Cytomegalovirus infections that are resistant or do not respond to available drugs are of even greater concern.
  • Today's approval helps meet a significant unmet medical need by providing a treatment option for this patient population."
  • CMV is a type of herpes virus that commonly causes infection in patients after a stem cell or organ transplant.
  • CMV infection can lead to CMV disease and have a major negative impact on transplant recipients, including loss of the transplanted organ and death.

ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs

Retrieved on: 
Wednesday, September 29, 2021
Biotechnology, AIDS, Health, Pharmaceutical, Clinical Trials, TAF, TANGO, ViiV Healthcare, GlaxoSmithKline, HIV, Pfizer, Virological failure, HIV-1, Pharmaceutical industry, TANGO2, Dovato (dolutegravir/lamivudine)3,4, ViiV Healthcare, GSK, TANGO2, DOVATO (DOLUTEGRAVIR/LAMIVUDINE)3,4, VIIV HEALTHCARE, GSK

Additionally, these data show no confirmed virologic failures, which is important over a long-term study.

Key Points: 
  • Additionally, these data show no confirmed virologic failures, which is important over a long-term study.
  • Participants were randomised to switch to dolutegravir/lamivudine or continue on the TAF-based regimens through Week 148.
  • Secondary endpoints included efficacy at Weeks 96 and 144 in the ITT-E and Per Protocol (PP) populations.
  • Dovato uses two medicines, instead of the traditional three, to inhibit the viral life cycle at two different sites.